دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Novel COVID-19 therapies: the road ahead for rheumatology
doi : 10.1016/S2665-9913(22)00007-8
Volume 4, Issue 2, February 2022, Page e73
Allogeneic mesenchymal stromal cell transplantation for systemic sclerosis
Elizabeth R Volkmann a, Wanxing Chai-Ho a
Abatacept for IgG4-related disease: therapeutic prospects according to disease immunophenotype
Yu Peng a, Wen Zhang a
Distinct immune response to CoronaVac in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic disease
doi : 10.1016/S2665-9913(21)00392-1
Volume 4, Issue 2, February 2022, Pages e77-e78
Predicting the risk of needing a total knee arthroplasty
doi : 10.1016/S2665-9913(21)00389-1
Volume 4, Issue 2, February 2022, Pages e78-e79
Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases
doi : 10.1016/S2665-9913(21)00356-8
Volume 4, Issue 2, February 2022, Pages e80-e82
Mental health before and during the pandemic in people with systemic sclerosis
doi : 10.1016/S2665-9913(21)00363-5
Volume 4, Issue 2, February 2022, Pages e82-e85
Immunomodulatory and immunosuppressive medication modification among patients with rheumatic diseases at the time of COVID-19 vaccination
doi : 10.1016/S2665-9913(21)00372-6
Volume 4, Issue 2, February 2022, Pages e85-e87
Rheumatoid arthritis, then and now
doi : 10.1016/S2665-9913(22)00005-4
Volume 4, Issue 2, February 2022, Page e89
Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study
doi : 10.1016/S2665-9913(21)00326-X
Volume 4, Issue 2, February 2022, Pages e91-e104
Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study
Mark A Matza MD a *, Cory A Perugino DO a b *, Liam Harvey BS a, Ana D Fernandes BS a, Zachary S Wallace MD a, Hang Liu MD b, Hugues Allard-Chamard PhD c, Prof Shiv Pillai PhD b, Prof John H Stone MD a
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study
doi : 10.1016/S2665-9913(21)00327-1
Volume 4, Issue 2, February 2022, Pages e113-e124
Prediction models for the risk of total knee replacement: development and validation using data from multicentre cohort studies
Qiang Liu MD a b †, Hongling Chu PhD c †, Prof Michael P LaValley PhD d, Prof David J Hunter PhD e f, Hua Zhang PhD c, Liyuan Tao PhD c, Prof Siyan Zhan PhD c g, Prof Jianhao Lin MD a, Prof Yuqing Zhang ScD b
Therapeutic implications of ongoing alveolar viral replication in COVID-19
doi : 10.1016/S2665-9913(21)00322-2
Volume 4, Issue 2, February 2022, Pages e135-e144
Industry involvement in rheumatology consensus-based recommendations: a systematic review
doi : 10.1016/S2665-9913(21)00332-5
Volume 4, Issue 2, February 2022, Pages e145-e152
